Icelandic BioTech Alvotech secures €100 million term loan facility to bolster liquidity and R&D investment

Alvotech, a Reykjavík-based BioTech firm being experts in the growth and manufacture of biosimilar medications, has actually safeguarded a EUR100 million elderly term financing center to enhance liquidity and sustain the implementation of its calculated concerns in 2026.

The term financing center births a rate of interest of 12.50%, payable month-to-month in money, and has a maturation day of 2 years. The deal, led by GoldenTree Property Administration, changes the firm’s formerly revealed functioning funding center (ABL) and supplies Alvotech with accessibility fully EUR100 million throughout of the financing term. The framework supplies improved functional versatility, Alvotech cases.

” This EUR100 million funding highlights the long-lasting dedication of our funding companions at GoldenTree and their positioning with Alvotech’s technique. Their assistance reinforces our capacity to perform on our development strategies, purchase R&D, and supply top quality biosimilars to individuals worldwide,” stated Robert Wessman, Chairman and Chief Executive Officer of Alvotech.

Established In 2013 by Wessman, Alvotech intends to be an international leader in the biosimilar domain name. ” A biosimilar is a biologic medication that is extremely comparable to and has no medically significant distinctions from an existing authorized biologic medication, or referral item. Biosimilars (like referral items) are created in living systems,” Alvotech discussed on its web site.

According to the Icelandic firm, 5 biosimilars are currently authorized and marketed in several international markets, consisting of biosimilars to Humira ® (adalimumab), Stelara ® (ustekinumab), Simponi ® (golimumab), Eylea ® (aflibercept) and Prolia ®/ Xgeva ® (denosumab).

Its existing growth pipe consists of 9 revealed biosimilar prospects targeted at dealing with autoimmune conditions, eye conditions, weakening of bones, breathing illness, and cancer cells.

In December 2025, Alvotech revealed the effective positioning of EUR91.9 million ($ 108 million) elderly unsafe exchangeable bonds due 2030. Furthermore, in June 2025, the firm revealed the repricing of its existing center to a rate of interest of SOFR plus 6.0% per year, comparable to about 9.8% based upon the 30-day ordinary SOFR price of ~ 3.8%. In June 2024, it revealed the effective plan of a calculated refinancing deal developing in June 2029, likewise led by GoldenTree Property Administration.

Alvotech specified that its R&D pipe presently consists of 30 items in growth. The firm is increasing its manufacturing ability and reinforcing its supply chain to sustain 4 international item launches intended with 2026.

The firm declares to have actually developed a network of industrial collaborations to sustain market gain access to in areas consisting of the USA, Europe, Japan, China, various other Oriental nations, and components of South America, Africa, and the Center East.

The message Icelandic BioTech Alvotech secures €100 million term loan facility to bolster liquidity and R&D investment showed up initially on EU-Startups.